Intra-Cellular announces results from Study 304 on lumateperone
The Fly

Intra-Cellular announces results from Study 304 on lumateperone

Intra-Cellular (ITCI) Therapies announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia. On the primary endpoint, time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone compared to those receiving placebo. There were 18 relapses in the lumateperone group versus 44 relapses in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App